Cassava Sciences Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while ProShares UltraPro Short QQQ ETF trades at $37.53. Which is the better fit depends on your goals.
| FLNA | SQQQ | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $92.95 |
52-Week Low | $0.87 | $36.31 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $37.32, down 1.11% amid a bearish technical signal with moving averages indicating selling pressure. The ETF is designed to deliver -3x the daily performance of the Nasdaq-100, making it highly sensitive to tech sector volatility. Recent news highlights its role as a tactical hedge tool but warns of significant long-term erosion due to daily reset mechanics.
The outlook for SQQQ remains high-risk, suitable only for short-term hedging against Nasdaq declines. Key risks include volatility decay from daily leverage and dependency on precise market timing. Investor sentiment is cautious, with analysts emphasizing its unsuitability as a long-term holding despite potential tactical opportunities during tech selloffs.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →